ALYMSYS
PeakmAbbevacizumab-maly
BLAINJECTIONINJECTABLE
Approved
Apr 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ALYMSYS (bevacizumab-maly) is vascular endothelial growth factor-directed antibody interactions [moa]. First approved in 2022.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALYMSYS (bevacizumab-maly) is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and suppressing neovascularization. It is a biosimilar formulation of bevacizumab approved in April 2022. The drug is administered via injection for oncology indications where VEGF inhibition is therapeutically indicated.
$0.486MPart D
PeakProduct is at peak lifecycle stage with modest Part D penetration; commercial teams should anticipate stable but competitive revenue as biosimilar alternatives emerge.
Mechanism of Action
Vascular Endothelial Growth Factor-directed Antibody Interactions
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ALYMSYS positions professionals in a mature, competitive biosimilar market requiring expertise in payer negotiations, clinical evidence communication, and market share defense. This role is ideal for those seeking to develop commercial oncology experience in a peak-stage product with stable but pressured revenue dynamics.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.